Previous studies suggested that FGL1 could be involved in the pathogenesis of MASLD [9, 10, 14, 15, 32] but it is unclear whether this contribution is protective or detrimental. This evidence concerns the gene FGL1 and metabolic dysfunction-associated steatotic liver disease.